Initial data from a Phase 1 study of bluebird bio’s second-generation CAR T-cell therapy bb2121 for relapsed or refractory multiple myeloma showed impressive results,…
A Phase 1 trial sponsored by Poseida Therapeutics for the company’s investigational CAR T-cell therapy for multiple myeloma, P-BCMA-101, is now enrolling participants. The…
Autolus has successfully completed dosing the first group of patients in a Phase 1/2 trial of AUTO2 — a CAR T-cell therapy that targets two…
Sellas Life Sciences’ cancer vaccine galinpepimut-S showed promising effects in patients with an aggressive form of multiple myeloma, researchers said in a presentation at…
Poseida Therapeutics demonstrated that their new CAR T-cell treatment for multiple myeloma — P-BCMA-101 — possessed features that make it stand out in the…
Lab tests used to evaluate treatment response after a stem cell transplant for multiple myeloma could lead physicians to wrongfully believe that a patient is…
The U.S. Food and Drug Administration has ordered Bristol-Myers Squibb to put a hold on three clinical trials evaluating Opdivo (nivolumab) in combination with…
The U.S. Food and Drug Administration (FDA) suspended a Phase 1 clinical trial testing a combination of AstraZeneca‘s Imfinzi (durvalumab) with an immunomodulatory and an anti-cancer…
Patients with relapsed or treatment-resistant multiple myeloma, who have undergone several earlier treatment rounds, have a much poorer response to combination treatments including Darzalex (daratumumab)…
BioLineRx is seeking regulatory approval to advance into a Phase 3 clinical trial its treatment BL-8040, for blood stem cell mobilization to prepare for autologous…